Market Place
Sourcing Support
Assertio says activist investor`s claims are `without merit`
12 Nov 2024 //
FIERCE PHARMA
Assertio Announces Favorable Vote on Proposed Acquisition of Spectrum Pharma
27 Jul 2023 //
GLOBENEWSWIRE
Spectrum`s Biologic Rolvedon (Eflapegrastim) Receives Approval in the U.S.
16 Jun 2023 //
FDA
Spectrum Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
17 May 2023 //
BUSINESSWIRE
Spectrum Pharmaceuticals Reports1Q 2023 FYR and Corporate Update
09 May 2023 //
BUSINESSWIRE
Assertio to buy commercial-stage biopharmaceutical firm Spectrum
26 Apr 2023 //
PHARMACEUTICAL TECHNOLOGY
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals
25 Apr 2023 //
GLOBENEWSWIRE
Spectrum Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
22 Mar 2023 //
BUSINESSWIRE
Spectrum to Report Fourth Quarter and Full Year 2022 Financial Results
17 Mar 2023 //
BUSINESSWIRE
Spectrum Receives Permanent J-Code for ROLVEDON Injection from U.S. CMS
08 Feb 2023 //
BUSINESSWIRE
Spectrum Pharmaceuticals Provides Update on ROLVEDON Injection
31 Jan 2023 //
BUSINESSWIRE
Spectrum Announces New Employment Inducement Grant for Commercial Staff
26 Jan 2023 //
BUSINESSWIRE
Law firms target Spectrum over lung cancer trial statements
24 Jan 2023 //
FIERCE BIOTECH
Spectrum Pharmaceuticals Announces Management Changes
04 Jan 2023 //
BUSINESSWIRE
Spectrum Pharma’s ROLVEDON Injection Added to NCCN Supportive Care Guidelines
06 Dec 2022 //
BUSINESSWIRE
Spectrum Pharma Announces New Employment Inducement Grants for Commercial Staff
05 Dec 2022 //
BUSINESSWIRE
Spectrum to lay off R&D staff after FDA drug rejection
29 Nov 2022 //
BIOPHARMADIVE
Spectrum implodes after aharsh public slapdown and a CRL from Richard Pazdur
28 Nov 2022 //
ENDPTS
FDA hands Hanmi’s partner, Spectrum, a poziotinib CRL for supplementary data
25 Nov 2022 //
KOREABIOMED
Spectrum Pharmaceuticals Reports 3Q 2022 Financial Results
10 Nov 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results
03 Nov 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON Injection
21 Oct 2022 //
BUSINESSWIRE
FDA committee vote against Spectrum`s Pozenveo
23 Sep 2022 //
FIERCEBIOTECH
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital
23 Sep 2022 //
BUSINESSWIRE
Knives out at ODAC with vote against accelerated approval for Spectrum drug
22 Sep 2022 //
ENDPTS
Spectrum Provides Update on Poziotinib Following FDA Oncologic Advisory Meeting
22 Sep 2022 //
BUSINESSWIRE
FDA staff flag concerns with cancer treatments from Spectrum, Oncopeptides
21 Sep 2022 //
REUTERS
Spectrum Announces Data from Presentation for Poziotinib in NSCLC Patients
10 Sep 2022 //
BUSINESSWIRE
Spectrum`s Biologic Rolvedon (Eflapegrastim) Receives Approval in the U.S.
09 Sep 2022 //
FDA
Spectrum Pharmaceuticals Shares Rise 12% on FDA Approval of Rolvedon
09 Sep 2022 //
ADVFN
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON Injection
09 Sep 2022 //
BUSINESSWIRE
Spectrum Announces Presentation for Poziotinib in NSCLC Patients
05 Sep 2022 //
BUSINESSWIRE
Spectrum Pharmas Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Spectrum Pharma to Report Second Quarter 2022 Financial Results
29 Jul 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
02 Jun 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals to Present Data at 2022 ASCO for Poziotinib
26 May 2022 //
BUSINESSWIRE
Spectrum Pharma to Participate in H.C. Wainwright Global Investment Conference
17 May 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
11 May 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results
06 May 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors
05 May 2022 //
BUSINESSWIRE
Spectrum Pharma Announces FDA Acceptance of BLA Resubmission for Eflapegrastim
11 Apr 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR
04 Apr 2022 //
BUSINESSWIRE
Spectrum Pharma Reports Q4 2021 and FY 2021 Financial Results
17 Mar 2022 //
BUSINESSWIRE
Spectrum Pharma to Report Q4 and Full Year 2021 Financial Results
11 Mar 2022 //
BUSINESSWIRE
Spectrum Pharma Appoints Juhyun Lim to Board of Directors
10 Mar 2022 //
BUSINESSWIRE
Spectrum Pharma Presents Positive Data for Poziotinib in First-line NSCLC
07 Mar 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces an Oral Poziotinib Presentation
28 Feb 2022 //
BUSINESSWIRE
Spectrum`s penny stock takes another hit as CFO quietly plans exit
23 Feb 2022 //
ENDPTS
Spectrum Pharma Announces Acceptance of NDA Filing for Poziotinib
11 Feb 2022 //
BUSINESSWIRE
Spectrum trims workforce, R&D to focus on 2 key cancer meds
06 Jan 2022 //
FIERCEBIOTECH
Spectrum Pharmaceuticals Announces Strategic Restructuring
05 Jan 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharma
04 Jan 2022 //
BUSINESSWIRE
Spectrum Pharmaceuticals to Participate in JMP Securities Hematology
29 Nov 2021 //
BUSINESSWIRE
Spectrum Pharmaceuticals Reports Q3 2021 Financial Results and Corporate Update
10 Nov 2021 //
BUSINESSWIRE
Spectrum Announces Presentation of Poziotinib with KRASG12C Inhibitors
07 Oct 2021 //
BUSINESSWIRE
Spectrum Presents Late Breaker Oral Presentation of Poziotinib Data
19 Sep 2021 //
BUSINESSWIRE
Esmo 2021 – poziotinib could add first-line string to its bow
17 Sep 2021 //
EVALUATE
Spectrum To Present Data of Poziotinib in First-Line NSCLC Patients at ESMO 2021
13 Sep 2021 //
BUSINESSWIRE
